Saquinavir mesylate
98%
- Product Code: 124929
CAS:
149845-06-7
| Molecular Weight: | 766.9465 g./mol | Molecular Formula: | C₃₉H₅₄N₆O₈S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00944907 | |
| Melting Point: | Boiling Point: | 1015℃ at 760 mmHg | |
| Density: | Storage Condition: | 2-8°C |
Product Description:
Saquinavir mesylate is primarily used as an antiretroviral medication in the treatment of HIV infection. It belongs to the protease inhibitor class, which works by blocking the activity of HIV protease, an enzyme essential for the replication of the virus. By inhibiting this enzyme, it prevents the virus from maturing and producing new infectious particles, thereby reducing the viral load in the body. It is often prescribed as part of a combination therapy known as highly active antiretroviral therapy (HAART) to enhance its effectiveness and minimize the risk of drug resistance. This medication is particularly beneficial for patients with advanced HIV or AIDS, helping to improve immune function and slow disease progression. It is typically administered orally in conjunction with other antiretroviral drugs to achieve optimal therapeutic outcomes.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | €42.74 |
+
-
|
Saquinavir mesylate
Saquinavir mesylate is primarily used as an antiretroviral medication in the treatment of HIV infection. It belongs to the protease inhibitor class, which works by blocking the activity of HIV protease, an enzyme essential for the replication of the virus. By inhibiting this enzyme, it prevents the virus from maturing and producing new infectious particles, thereby reducing the viral load in the body. It is often prescribed as part of a combination therapy known as highly active antiretroviral therapy (HAART) to enhance its effectiveness and minimize the risk of drug resistance. This medication is particularly beneficial for patients with advanced HIV or AIDS, helping to improve immune function and slow disease progression. It is typically administered orally in conjunction with other antiretroviral drugs to achieve optimal therapeutic outcomes.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :